Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 7/20 | 0.44 |
| ▸ | MMP2 | P08253 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25747761 | 0.85 | MMP3 (0.44) | HRH3MMP3MMP2ALDH1A1MAPT | |
| SCHEMBL23499617 | 0.85 | MMP3 (0.44) | HRH3MMP3MMP2ALDH1A1MAPT | |
| SCHEMBL25040486 | 0.85 | MMP2 (0.44) | MMP3MMP2ALDH1A1MAPTMMP1 | |
| SCHEMBL25747856 | 0.84 | L3MBTL1 (0.43) | ALDH1A1MAPTCTSARARARARB | |
| SCHEMBL25040493 | 0.81 | PDE4A (0.50) | — | |
| SCHEMBL15499160 | 0.80 | MAPT (0.45) | MMP3MMP2ALDH1A1MAPTMMP1 | |
| SCHEMBL25040867 | 0.80 | HRH3 (0.49) | HRH3MMP3MMP2KIF11MMP1 | |
| SCHEMBL7228479 | 0.79 | HRH3 (0.56) | HRH3MMP3MMP2KIF11MMP1 | |
| SCHEMBL9062436 | 0.78 | HRH3 (0.55) | HRH3ALDH1A1KIF11RARARARB | |
| SCHEMBL15499159 | 0.77 | MAPT (0.44) | MMP3MMP2ALDH1A1MAPTMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-07-04 | — | — | US | disclosed |
| US-20230051259-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051259-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | HRH3 4831/4885MMP3 4655/4885MMP2 4033/4885 |
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | HRH3 4831/4885MMP3 4655/4885MMP2 4033/4885 |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | UGT1A4, TBK1, UGT1A7 | HRH3 4831/4885MMP3 4655/4885MMP2 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.